ImmuPharma (LON:IMM) Releases Quarterly Earnings Results

ImmuPharma (LON:IMM) released its quarterly earnings results on Monday. The company reported GBX (0.60) (($0.01)) EPS for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%.

ImmuPharma Stock Performance

LON:IMM opened at GBX 2.93 ($0.04) on Monday. ImmuPharma has a one year low of GBX 0.85 ($0.01) and a one year high of GBX 7.40 ($0.10). The business’s 50-day simple moving average is GBX 2.91 and its 200 day simple moving average is GBX 2.72. The stock has a market cap of £12.46 million, a price-to-earnings ratio of -5.07 and a beta of 1.53.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.